2.9800
22-November-24 15:44:58
15 minutes delayed
Stocks
+0.0900
+3.11%
Today's range
2.8800 - 3.0000
ISIN
N/A
Source
NASDAQ
Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors
18 Sep 2024 07:30:00 By Nasdaq GlobeNewswire